Serological assays that can reveal immune status against COVID-19 play a critical role in informing individual and public healthcare decisions. Currently, antibody tests are performed in central clinical laboratories, limiting broad access to diverse populations. Here we report a multiplexed and label-free nanoplasmonic biosensor that can be deployed for point-of-care antibody profiling. Our optical imaging-based approach can simultaneously quantify antigen-specific antibody response against SARS-CoV-2 spike and nucleocapsid proteins from 50 µL of human sera. To enhance the dynamic range, we employed multivariate data processing and multi-color imaging and achieved a quantification range of 0.1-100 µg/mL. We measured sera from a COVID-19 acute and convalescent (N = 24) patient cohort and negative controls (N = 5) and showed highly sensitive and specific past-infection diagnosis. Our results were benchmarked against an electrochemiluminescence assay and showed good concordance (R∼0.87). Our integrated nanoplasmonic biosensor has the potential to be used in epidemiological sero-profiling and vaccine studies.

Serological assays can reveal immune status against COVID-19 informing individual and public healthcare decisions. We report a multiplexed and label-free nanoplasmonic biosensor that can discriminate healthy from convalescent samples with high sensitivity (95%) and specificity (100%) based on anti-SARS-CoV-2 antibody quantification. Our results show high concordance (R~ 0.87) with commercial assays in detecting anti-SARS-CoV-2 antibodies.